细胞因子诱导的杀伤细胞对裸鼠人胰腺肿瘤移植瘤生长的抑制作用。
Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model.
机构信息
College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea.
出版信息
Immune Netw. 2012 Dec;12(6):247-52. doi: 10.4110/in.2012.12.6.247. Epub 2012 Dec 31.
Pancreatic cancer is the fourth commonest cause of cancer-related deaths in the world. However, no adequate therapy for pancreatic cancer has yet been found. In this study, the antitumor activity of cytokine-induced killer (CIK) cells against the human pancreatic cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 for 14 days. The resulting populations of CIK cells comprised 94% CD3(+), 4% CD3(-)CD56(+), 41% CD3(+)CD56(+), 11% CD4(+), and 73% CD8(+). This heterogeneous cell population was called cytokine-induced killer (CIK) cells. At an effector-target cell ratio of 100:1, CIK cells destroyed 51% of AsPC-1 human pancreatic cancer cells, as measured by the (51)Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 42% and 70% of AsPC-1 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for pancreatic cancer patients.
胰腺癌是全球第四大常见癌症相关死因。然而，目前尚未找到治疗胰腺癌的充分方法。本研究评估了细胞因子诱导的杀伤（CIK）细胞在体外和体内对人胰腺癌的抗肿瘤活性。将人外周血单核细胞用含有 IL-2 的培养基和抗 CD3 抗体培养 14 天。由此产生的 CIK 细胞群体中包含 94%的 CD3(+)、4%的 CD3(-)CD56(+)、41%的 CD3(+)CD56(+)、11%的 CD4(+)和 73%的 CD8(+)。这种异质细胞群被称为细胞因子诱导的杀伤（CIK）细胞。在效应细胞-靶细胞比例为 100:1 时，CIK 细胞通过（51）Cr 释放试验破坏了 51%的 AsPC-1 人胰腺癌细胞。此外，在裸鼠异种移植模型中，CIK 细胞剂量为每只小鼠 300 万和 1000 万个细胞时，分别抑制了 42%和 70%的 AsPC-1 肿瘤生长。本研究表明，CIK 细胞可能被用作胰腺癌患者的过继免疫疗法。
Zotero 插件